Drugs /

axitinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
axitinib
Trade Name(s):
Inlyta
NCI Definition [1]:
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.

Clinical Trials

View Clinical Trials for axitinib

Axitinib has been investigated in 31 clinical trials, of which 27 are open and 4 are closed. Of the trials investigating axitinib, 5 are phase 1 (4 open), 7 are phase 1/phase 2 (6 open), 16 are phase 2 (14 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open).

EGFR Exon 19 Deletion, EGFR L858R, and EGFR L861Q are the most frequent biomarker inclusion criteria for axitinib clinical trials.

Clear cell renal cell carcinoma, renal cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in axitinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Axitinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Axitinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating axitinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ag-013736, Inlyta, axitinib (product), axitinib, axitinib (substance), axitinib, ag013736, ag 013736, n-methyl-2-((3-((1e)-2-(pyridin-2-yl)ethenyl)-1h-indazol-6-yl)sulfanyl)benzamide
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB
NCIT ID [1]:
C38718
SNOMED ID [1]:
C-78207

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.